Targeted Nanosystems for Cancer Therapy

Author(s): Ruhee Jain, Tahseen Khan, Sourabh Jain, Ashutosh Pal Jain, Aakanchha Jain*.

Journal Name: Current Cancer Therapy Reviews

Volume 13 , Issue 1 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Significant shortcomings have been displayed in conventional chemotherapeutics delivery which possesses some genuine side effects including harm of the immunity and different organs with quickly multiplying cells because of nonparticular focus on the absence of dissolvability and powerlessness to enter the tumor core bringing about debilitated treatment with diminished dosage and with low survival rate. Rapid development has adapted nanocarriers as distinct therapeutics which can directly access the tumor cells specifically with expanded medication limitation and cell take-up for cancer treatment.

Methodology: This review focuses on core objective of drug targeting to the cancerous cells by demonstrating the advantages of the young medical field, “nanocarriers” including liposomes, polymer based nanoparticles, metal based nanoparticles, dendrimers, protein linked systems, co-polymers and fullerenes, which have been proven remarkably promising in enhancing drug distribution and bioavailability, increasing half life and achieving targeted drug delivery, thus reducing toxicity.

Conclusion: Here we provide an update on the recent clinical trials in nanocarrier based therapy of colon rectal cancer, food and drug administration (FDA) approved nanomedicines for cancer and those in nanoplatforms which have reached an advanced stage of clinical development.

Keywords: Chemotherapeutics, clinical trials, dendrimers, fullerenes, liposomes, nanocarriers.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 1
Year: 2017
Page: [63 - 73]
Pages: 11
DOI: 10.2174/1573394713666170622104347
Price: $58

Article Metrics

PDF: 22
HTML: 2